This indefinite delivery contract was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to support pediatric immunization programs. The contract holder will provide up to 23 standard pediatric vaccines to CDC without a set-aside designation. Vaccines must be manufactured under current FDA licensure with a minimum 12-month shelf life.
The multiple award IDV has a potential value of $1.5B to be ordered by March 2023 for delivery within the United States. The sole awardee is Pfizer Inc. to supply minimum and maximum doses of each pediatric vaccine type listed in the original solicitation. Vaccines will support immunization programs under Section 317(j) of the Public Health Service Act and the Vaccines for Children program, as established in OBRA 1993. The period of performance is April 2022 through March 2023.
Generated 1/4/24, 10:34 PM